218 related articles for article (PubMed ID: 33037919)
21. Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin.
Kako S; Gomyo A; Akahoshi Y; Harada N; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Kanda J; Kanda Y
Eur J Haematol; 2019 Mar; 102(3):256-264. PubMed ID: 30578673
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation.
Meyer RG; Britten CM; Wehler D; Bender K; Hess G; Konur A; Hartwig UF; Wehler TC; Ullmann AJ; Gentilini C; Uharek L; Huber C; Kolbe K; Herr W
Blood; 2007 Jan; 109(1):374-82. PubMed ID: 16940425
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab for the prevention and treatment of graft-versus-host disease.
Kanda J; Lopez RD; Rizzieri DA
Int J Hematol; 2011 May; 93(5):586-593. PubMed ID: 21369856
[TBL] [Abstract][Full Text] [Related]
24. Repeated CD45RA-depleted DLI successfully increases donor chimerism in a patient with beta-thalassemia major after haploidentical stem cell transplant.
Chan WYK; Kwok JSY; Chiang AKS; Chan GCF; Lee PPW; Ha SY; Cheuk DKL
Pediatr Transplant; 2021 Aug; 25(5):e13945. PubMed ID: 33314508
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in Asian Patients with Inborn Errors of Immunity.
Miyamoto S; Niizato D; Tomomasa D; Nishimura A; Hoshino A; Kamiya T; Isoda T; Takagi M; Kajiwara M; Azumi S; Hirabayashi S; Sakamoto K; Kishimoto K; Miyamura T; Umeda K; Hirose A; Keino D; Yanagimachi M; Kanda K; Sakai Y; Ikawa Y; Watanabe K; Tanaka K; Mori T; Ichinohe T; Sakaguchi H; Morio T; Kanegane H
J Clin Immunol; 2024 May; 44(6):126. PubMed ID: 38773000
[TBL] [Abstract][Full Text] [Related]
26. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.
Dodero A; Carniti C; Raganato A; Vendramin A; Farina L; Spina F; Carlo-Stella C; Di Terlizzi S; Milanesi M; Longoni P; Gandola L; Lombardo C; Corradini P
Blood; 2009 May; 113(19):4771-9. PubMed ID: 19211934
[TBL] [Abstract][Full Text] [Related]
27. In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation.
Kanda Y; Oshima K; Asano-Mori Y; Kandabashi K; Nakagawa M; Sakata-Yanagimoto M; Izutsu K; Hangaishi A; Tsujino S; Ogawa S; Motokura T; Chiba S; Hirai H
Transplantation; 2005 May; 79(10):1351-7. PubMed ID: 15912103
[TBL] [Abstract][Full Text] [Related]
28. Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation.
Davies JK; Brennan LL; Wingard JR; Cogle CR; Kapoor N; Shah AJ; Dey BR; Spitzer TR; de Lima M; Cooper LJ; Thall PF; Champlin RE; Nadler LM; Guinan EC
Clin Cancer Res; 2018 Sep; 24(17):4098-4109. PubMed ID: 29769208
[No Abstract] [Full Text] [Related]
29. Haploidentical HCT using an αβ T-cell-depleted graft with targeted αβ(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI.
Im HJ; Koh KN; Suh JK; Lee SW; Choi ES; Jang S; Kwon SW; Park CJ; Seo JJ
Bone Marrow Transplant; 2016 Sep; 51(9):1217-22. PubMed ID: 27159171
[TBL] [Abstract][Full Text] [Related]
30. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
Bashey A; Solomon SR
Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome.
Admiraal R; Jol-van der Zijde CM; Furtado Silva JM; Knibbe CAJ; Lankester AC; Boelens JJ; Hale G; Etuk A; Wilson M; Adams S; Veys P; van Kesteren C; Bredius RGM
Clin Pharmacokinet; 2019 Dec; 58(12):1609-1620. PubMed ID: 31131436
[TBL] [Abstract][Full Text] [Related]
32. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
33. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
[TBL] [Abstract][Full Text] [Related]
34. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
[TBL] [Abstract][Full Text] [Related]
35. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis.
Ghosh N; Karmali R; Rocha V; Ahn KW; DiGilio A; Hari PN; Bachanova V; Bacher U; Dahi P; de Lima M; D'Souza A; Fenske TS; Ganguly S; Kharfan-Dabaja MA; Prestidge TD; Savani BN; Smith SM; Sureda AM; Waller EK; Jaglowski S; Herrera AF; Armand P; Salit RB; Wagner-Johnston ND; Fuchs E; Bolaños-Meade J; Hamadani M
J Clin Oncol; 2016 Sep; 34(26):3141-9. PubMed ID: 27269951
[TBL] [Abstract][Full Text] [Related]
36. A comparative study of reduced dose alemtuzumab in matched unrelated donor and related donor reduced intensity transplants.
Jardine L; Publicover A; Bigley V; Hale G; Pearce K; Dickinson A; Jackson G; Collin M
Br J Haematol; 2015 Mar; 168(6):874-81. PubMed ID: 25640315
[TBL] [Abstract][Full Text] [Related]
37. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1.
Marsh RA; Bleesing JJ; Chandrakasan S; Jordan MB; Davies SM; Filipovich AH
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1641-5. PubMed ID: 24923536
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia.
Thakar MS; Bonfim C; Sandmaier BM; O'Donnell P; Ribeiro L; Gooley T; Deeg HJ; Flowers ME; Pasquini R; Storb R; Woolfrey AE; Kiem HP
Pediatr Hematol Oncol; 2012 Sep; 29(6):568-78. PubMed ID: 22839094
[TBL] [Abstract][Full Text] [Related]
39. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
[TBL] [Abstract][Full Text] [Related]
40. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
Exp Hematol; 1999 Jul; 27(7):1210-8. PubMed ID: 10390197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
